Company ProfilePremium

Shofu Inc.

Company Profile Analysis

Ticker: 7979.T株式会社松風

ESOMAR 23 Corporate BadgeISO Certifications Badge
Shofu Inc. - Company showcase

Year Founded & Workforce

1922

1,462 Employees

Shofu Inc. logo

Shofu Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Shofu Inc. Overview

SHOFU is Japan's oldest and one of its most diversified dental consumables manufacturers, tracing its roots to the country's first high-quality porcelain artificial teeth in 1922. The company spans the full restorative workflow — artificial teeth, abrasives and polishing systems, composite resins, adhesives, cements, ceramics, CAD/CAM blocks and discs, and clinical equipment such as intraoral photography cameras — serving dental clinics and dental laboratories through dealers in Japan and wholly owned sales subsidiaries in the US, Germany, the UK, China, Singapore, India, Brazil and, since 2026, the Middle East. Its signature intellectual property is Giomer/S-PRG bioactive filler technology, embedded in the BEAUTIFIL composite family. With a debt-free balance sheet, an equity ratio above 80%, and overseas sales near 59% of revenue, SHOFU is a mid-cap niche consolidator that has set itself a ¥50bn sales target for FY2028 and an aspirational ¥250bn, 20%-margin "global top-10" goal for 2040.


Company's own description

The Yuho FY2026 describes the group as comprising SHOFU INC., 18 consolidated subsidiaries, one unconsolidated subsidiary, one equity-method affiliate (Sun Medical Co., Ltd.) and one "other affiliated company" (Mitsui Chemicals). The group operates as a comprehensive manufacturer of dental materials and equipment, with two smaller adjacent businesses: nail-care products and industrial abrasives. The Yuho identifies the main dental product families as artificial teeth, abrasives (grinding and polishing), dental metals, chemical products (restoratives, adhesives, CAD/CAM materials), cements, and machinery and instruments.

The corporate philosophy is to contribute to global dental care through creative corporate activity. The corporate message used in investor materials translates as "supporting the ability to chew, smile and live."

Business model and revenue model

Revenue typeShare of revenueComment
Product sales (consumables)Large majority (precise split n.d.)Restoratives, abrasives, artificial teeth, cements, CAD/CAM materials
Product sales (equipment)Minor share (n.d.)Intraoral cameras, laboratory equipment, curing devices
Repair / after-sales serviceMinor (n.d.)Equipment repair services; order backlog ¥494m at FY2026 end, all dental
Subscription / licensingNot materialCAD software "Go2 dental" is updated periodically; licensing revenue not separately disclosed

SHOFU runs a vertically integrated, product-sale business model. It does R&D in Kyoto (and at subsidiaries in Germany and the UK), manufactures in Japan (Kyoto, Shiga, Kumiyama), China (Shanghai, Changzhou), Vietnam, Germany and the UK, and sells primarily through dental dealers (domestically and in most export markets), supported by its own sales subsidiaries and a "academic network" of key opinion leaders.

Revenue recognition is at delivery to customers (domestic sales recognised at shipment under the alternative treatment; exports recognised at shipment/loading under trade terms), per the Yuho FY2026 accounting policies. No single customer exceeds 10% of consolidated sales.

Value-chain position

SHOFU sits in the manufacturer tier of the dental value chain. It sources chemical and ceramic raw materials, adds value through proprietary filler chemistry, ceramics processing and precision abrasive manufacture, and relies on distributors (dental dealers) to reach end users. In Japan it is also a key supplier into the national health insurance-reimbursed restorative market, notably CAD/CAM crowns made from resin-based blocks and PEEK.

Customer types and end-markets

Dental clinics (chairside): composites (BEAUTIFIL), adhesives (BeautiBond), cements, polishing systems, preventive products, orthodontic materials, intraoral cameras.

Dental laboratories (labside): artificial teeth, porcelain and stains (Vintage line), indirect composites (Ceramage), CAD/CAM blocks and discs, laboratory abrasives.

Dental dealers: primary channel in Japan, North America and Europe.

Nail salons and consumers: gel and acrylic nail systems (Nail Labo).

Industrial users: rubber-bonded abrasives for moulds, ceramics and plastics (SHOFU Products Kyoto).

Independent characterisation

SHOFU is best understood as a restorative-materials specialist with a strong legacy franchise in prosthetics (artificial teeth, abrasives) that is pivoting toward digital dentistry (CAD/CAM materials, software, intraoral imaging) and overseas growth. Its competitive edge is chemistry-led differentiation (Giomer/S-PRG bioactive fillers) rather than scale. The economics show high gross margins (~59%) but SG&A-heavy cost structures (~46% of sales), typical of a mid-sized dental consumables player that must maintain dealer support, clinical education and multi-country regulatory compliance without the scale advantages of Dentsply Sirona or Envista. The Mitsui Chemicals capital tie-up (20.11%) gives SHOFU a strategic anchor shareholder that also owns competitor-cum-partner businesses (Kulzer and Sun Medical).

Strategy

Stated strategy (Yuho FY2026, paraphrased)

Management philosophy: contribute to global dental care through creative corporate activity; pursue quantitative growth while prioritising quality; anticipate change and take on challenges.

Long-term vision "Vision10" (announced December 2025): become a global top-10 dental company by 2040, positioned as a leading company in digital dentistry and oral care. Targets for 2040: group net sales of ¥250bn and operating profit of ¥50bn (20% margin) — roughly 5x sales and 6.6x operating income versus FY2028 plan levels.

Three strategic pillars of Vision10: (1) strengthen the core restorative-materials franchise; (2) accelerate global and digital initiatives in growth areas (digital dentistry, prevention, orthodontics); (3) explore new domains (periodontal disease, sleep dentistry, diagnostic devices) via organic growth, alliances and M&A.

Fifth Medium-Term Management Plan (FY2025–FY2028)

TargetFY2028 goal
Group net sales¥50.1bn (Japan ¥18.7bn; overseas ¥31.4bn)
Operating profit¥7.5bn (15% margin)
ROE13.5% (from 9.5% in FY2024)
Production-capacity capex¥9bn (Kyoto head office plant ¥3.7bn; domestic bases ¥3.1bn; overseas bases ¥2.2bn)
Cross-shareholdingsReduce to ~10% of net assets (from ~20% in FY2024; 16.3% at FY2026)
Shareholder returnConsolidated payout ≥40% and DOE ≥3.0%

The "¥50 billion Vision" dates from 2012 and has been deferred several times (originally 2022, then 2027, now FY2028), per the company's integrated report.

FY2026 priority issues (Yuho): region-specific new products; sales network and bases; domestic and overseas academic networks; relocation of production and expansion of overseas manufacturing; global talent; funding for higher capital needs; M&A (business/technology alliances and acquisitions); group governance; the Mitsui Chemicals / Sun Medical alliance; and sustainability management.

Initiatives in the last 24 months

InitiativeStatus / detail
Kyoto head-office plant rebuild ("SMILE FACTORY TAKUMI")Phase 1 completed Mar 2026; full completion Aug 2028; budget ¥4,091m
Shiga Shofu new plant¥1,370m, loan-financed; completion Dec 2026
Changzhou (China) manufacturingEstablished Apr 2024
Middle East & Africa sales subsidiaryConsolidated Q1 FY2027
Implant business integrationSHOFU BIOFIX absorbed 1 Oct 2026 to strengthen digital-dentistry system proposals
US entity rationalisationSmart Dentistry Solutions merged into SHOFU Dental Corp., Jan 2026
Capital-efficiency programme (May 2024, updated May 2025)ROE target 13.5%; liquidity measures (stock split Oct 2024); takeover defence removed
Cross-shareholding unwinding4 listed holdings sold in FY2026 (¥1,124m); further ¥1,124m gain in Q1 FY2027; proceeds to capex and special dividends
Human capitalGlobal, DX and next-generation leadership talent pipelines; consolidated-linked employee bonus from summer 2026
SustainabilityScope 1+2 −27% by FY2030 vs FY2021; carbon neutral by 2050

Near-term guidance (FY2027, issued 13 May 2026; unchanged at Q1)

MetricH1 FY2027 guidanceFY2027 guidanceYoY (FY)
Net sales (JPY m)20,66942,958+7.4%
Operating profit (JPY m)2,9496,003+14.9%
Ordinary profit (JPY m)2,8615,890+0.5%
Net profit (JPY m)2,5524,756-2.7%
EPS (JPY)71.73133.66—
DPS (JPY)39 (incl. 12 special)67+11.7%

Products & Services

Pricing is not publicly disclosed at group level; most dental consumables are sold through dealers at list prices, and in Japan many restorative products are priced against national health insurance reimbursement schedules. Launch dates below are from the Yuho FY2026 R&D section where stated; otherwise "n.d.".

Dental-related Business — Chairside restoratives and adhesives

ProductDescription / capabilitiesTarget customerLatest version / date
BEAUTIFIL family (incl. BEAUTIFIL II, BEAUTIFIL Flow Plus)Giomer composites containing S-PRG filler that release and recharge fluoride and other ionsGeneral dentistsOngoing line; flagship franchise
BEAUTIFIL II LSLow-shrinkage composite resinDentists (Europe launch)Launched in Europe, August 2025
BeautiBond adhesive familySelf-etch bonding agentsDentists—
SHOFU Etchant40% phosphoric acid gel for selective enamel etching, successor to Imperva Bond Etching GelDentistsAugust 2025
Cements (incl. resin and glass-ionomer types)Luting and restorative cements; management cites cements as a priority export categoryDentists—

Dental-related Business — CAD/CAM and digital

ProductDescription / capabilitiesTarget customerLatest version / date
SHOFU Disk ZR Lucent SupraZirconia ceramic disc for millingDental labsKey growth driver FY2026 (Japan and Europe)
SHOFU Block HC Super HardHybrid resin block for milling crownsLabs / clinics (Japan insurance-reimbursed CAD/CAM crowns)Key growth driver FY2026
SHOFU Block PEEKPEEK block for milling crownsLabs / clinics (Japan)Key growth driver FY2026
Go2 dentalCAD softwareLabsVersion updates August and December 2025
EyeSpecial digital camera seriesIntraoral / clinical photography camerasDentistsCited as a driver of FY2025 domestic sales (secondary source)
S-WAVE CAD/CAM Processing CenterContract milling service in Kumiyama, KyotoDental labs (Japan)Operating since 2014
Digital Dental Services GmbHDigital processing and sales service in GermanyLabs (Europe)Subsidiary of Merz Dental

Dental-related Business — Laboratory materials and prosthetics

ProductDescription / capabilitiesTarget customerLatest version / date
Artificial teeth (resin and porcelain)The company's founding product category; Merz Dental supplies European denture teethDental labs—
Vintage Art Universal GumCeramic stains adding 15 gum shades and 2 depth-adjusting materials to 29 crown shadesDental labsAugust 2025
Vintage porcelain systemsFeldspathic and layering porcelainDental labs—
Indirect composites (Ceramage line)Lab-processed composite for crowns/veneersDental labs—
Dental metalsAlloys for prostheticsDental labs—

Dental-related Business — Abrasives, polishing and preventive care

ProductDescription / capabilitiesTarget customerLatest version / date
Abrasives and diamond/carbide bursGrinding, cutting and finishing instruments — a historic domestic leadership categoryClinics and labs—
Polishing systemsComposite and ceramic polishing discs, points and wheelsClinics and labs—
Merssage Pro One Paste / TT Plus / Stain OffRenewed professional prophylaxis pastes with medicated ingredientsDentists, hygienistsJuly 2025
PTM KitPeriodontal severity test kit, redesigned with 4 wells per tray (from 16)DentistsSeptember 2025 renewal
ShaburioOral-function training device for elderly patients (lip, tongue and facial muscles)Clinics treating oral hypofunctionSeptember 2025

Dental-related Business — Orthodontics and implants

ProductDescription / capabilitiesTarget customerLatest version / date
Genius Metal / Genius Crystal bracketsMetal and ceramic orthodontic bracketsOrthodontistsExisting; SHOFU Tube added December 2025
SHOFU TubeMolar tube bracket for second molars, sold alone or in kitsOrthodontistsDecember 2025
EvenForce NT Closed Coil SpringLow-force orthodontic spring to reduce patient discomfortOrthodontistsDecember 2025
Beauty Ortho AttachmentResin material for aligner attachmentsOrthodontists / aligner providersSeptember 2025
Implant business (formerly SHOFU BIOFIX)Sale of dental implant systems; folded into SHOFU INC. from 1 Oct 2026 to strengthen digital-dentistry system proposalsDentistsBrand details n.d.

Dental-related Business — Equipment and services

Machinery and instruments for clinics and labs, plus repair services (order backlog ¥494m at 31 March 2026). Third-party products are also distributed (e.g., ultrasonic scalers sourced from Nakanishi; paediatric crown products from Shinhung, per the Yuho cross-shareholding disclosures).

Nail-related Business

BrandDescriptionTargetLatest launches
PRESTOVisible-light LED-cure gel nail system (flagship)Professional nail artistsMolding Gel and Putty Gel colours (May 2025); Clean Bond Primer and Mag Plus top gels (Nov 2025); 48 new colours
agehaGel system co-developed with a well-known nail artistProfessionalsNew art gels (Feb–Mar 2026); 32 new colours
ARTiS di VoceMid/low-price gel and hand-care system for Asian marketsProfessionals in Asia (Taiwan focus)40 brush-on colours planned by Nail Labo Taiwan
by Nail LaboAt-home gel systemConsumersPlump Top Gel (Nov 2025); 11 colours
NAIL DE DANCEAcrylic nail system using dental-material technologyProfessionalsNew powders (May, Jul, Nov 2025)

Other Businesses

Industrial rubber-bonded abrasives for hard ceramics and soft plastics, plus grinding/cutting materials, sold mainly into automotive mould-making (SHOFU Products Kyoto). FY2026 sales ¥99m.

Financial Narrative

Income statement

DPS note: reported pre-split DPS were ¥39 (FY2022, incl. ¥2 centenary), ¥57 (FY2023, incl. ¥10 centenary), ¥62 (FY2024); FY2025 ¥49 and FY2026 ¥60 (incl. ¥5 special) are post-split.

Margins (%; derived)

Revenue CAGR FY2022–FY2026: 9.2% (derived). Operating profit CAGR: 12.9%. Net profit CAGR: 17.7%.

EBITDA

S&P reports TTM EBITDA to June 2026 of ¥6.92bn.

Balance sheet

No goodwill is recorded on the consolidated balance sheet. Lease liabilities (IFRS 16 at overseas subsidiaries) are excluded from "total debt" above. At 30 June 2026 the company drew new long-term loans totalling ¥1,318m (¥325m current, ¥993m non-current), consistent with the debt-financed Shiga Shofu plant plan; net cash at that date was ¥11,224m. Investment securities at 31 March 2026 were ¥10,112m, of which listed cross-shareholdings were ¥7,938m (16.3% of net assets).

Cash flow

Sign convention: investing and financing flows shown negative as outflows. The Yuho's five-year table lists absolute values; the direction is confirmed by the detailed FY2025–FY2026 statements.

Ratios (derived unless stated)

ROIC methodology: NOPAT (operating profit × (1 − effective tax rate)) divided by operating invested capital (net assets + debt − cash − investment securities). S&P reports TTM ROIC of 14.5%.

Commentary on trends, inflections and drivers

Growth. FY2022–FY2025 delivered four consecutive years of double-digit growth driven by overseas expansion (overseas ratio up from 49.4% to 58.6%), CAD/CAM materials in Japan, and yen weakness that inflated translated overseas sales. FY2026 marked a clear inflection to low single-digit growth (+3.3%): Q1–Q3 cumulative sales grew only 0.9%, reflecting weaker demand for certain products in Japan and difficult overseas conditions (Middle East disruption in Europe; US tariff uncertainty). Q4 FY2026 (¥10,880m) and Q1 FY2027 (¥10,788m, +13.5%) indicate a re-acceleration.

Profitability. Operating margin expanded from 11.4% to 13.9% through FY2025 on gross-margin gains (+1.9pt to FY2025) and SG&A leverage, then dipped to 13.1% in FY2026 as SG&A rose 5.2% against 3.3% sales growth. Below the operating line, two recurring supports flatter earnings: (1) cross-shareholding sales (gains of ¥681m in FY2025, ¥836m in FY2026 and ¥1,124m in Q1 FY2027 alone), and (2) non-operating items (FX gains, ¥198m sale of stored goods in FY2026). FY2026 record net profit (+13.2%) therefore overstates underlying operating momentum (OP −3.1%).

Balance sheet. Exceptionally conservative: no financial debt at FY2025–FY2026 year-ends, equity ratio 84%, a retirement benefit asset (overfunded pension) of ¥2.46bn, and an unused ¥2bn commitment line. The capital-efficiency weakness is visible in ROE (10.7%) versus the 13.5% FY2028 target, driven by large cash and cross-holdings.

Working capital — the key red flag. Inventory rose from ¥7.6bn to ¥13.8bn (+82%) over four years while sales rose 42%; DIO went from 230 to 309 days. Management attributes the FY2026 increase mainly to merchandise and finished goods, consistent with building stock ahead of plant transitions and for overseas channels. This is why OCF has stagnated around ¥3.1–3.7bn despite net profit nearly doubling, and why FY2026 FCF turned negative once plant capex stepped up.

Capex cycle. FY2026 capex of ¥4.4bn (¥2.1bn on the Kyoto new plant) sits within the Fifth MTP's ¥9bn production-capacity envelope. The Kyoto head-office plant rebuild has a ¥4,091m budget (¥2,251m spent) completing August 2028; the Shiga Shofu new plant (¥1,370m, borrowed funds) is scheduled for December 2026.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsMain productsOperating entities

Dental-related Business (デンタル関連事業)

Manufacture, sale and repair of dental materials and equipment

Artificial teeth, abrasives, metals, chemical products (restoratives, adhesives, CAD/CAM), cements, machinery & instruments

SHOFU INC., Shiga Shofu, SHOFU Products Kyoto, SHOFU BIOFIX (merged Oct 2026), SHOFU Dental Corp. (US), SHOFU Dental GmbH, Advanced Healthcare (UK), Merz Dental (DE), Digital Dental Services (DE), Shanghai and Changzhou manufacturing, Shanghai trading, Asia-Pacific (SG), India, Brazil, Vietnam, Middle East & Africa

Nail-related Business (ネイル関連事業)

Gel and acrylic nail systems and equipment

PRESTO, ageha, ARTiS di Voce, by Nail Labo, NAIL DE DANCE

Nail Labo Co., Nail Labo Inc. (US), Taiwan Nail Labo (70%), Shiga Shofu (manufacture)

Other Businesses (その他の事業)

Industrial abrasives derived from dental abrasive technology

Rubber-bonded abrasives for hard ceramics and soft plastics

SHOFU Products Kyoto

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2025FY2026

Dental net sales (JPY Mn)

36,35637,669

Nail net sales (JPY Mn)

2,2432,225

Other net sales (JPY Mn)

9899

Dental operating profit (JPY Mn)

5,4385,334

Nail operating profit (JPY Mn)

-67-113

Other operating profit (JPY Mn)

140

Dental operating margin (%)

15.014.2

Nail operating margin (%)

-3.0-5.1

Dental share of group sales (%)

93.994.2

Nail share of group sales (%)

5.85.6

Other share of group sales (%)

0.30.2

Revenue by Segment and Segment Margins & Growth (%) (Quarterly)

MetricQ1 FY2026Q1 FY2027

Dental net sales (JPY Mn)

8,96510,247

Nail net sales (JPY Mn)

518516

Other net sales (JPY Mn)

2225

Dental segment profit (JPY Mn)

1,5352,004

Nail segment profit (JPY Mn)

-42-61

Other segment profit (JPY Mn)

0-1

Dental segment margin (%)

17.119.6

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Net sales (JPY Mn)

28,13731,67835,08038,69839,994

Revenue growth (%)

14.012.610.710.33.3

Gross profit (JPY Mn)

16,16718,69920,99622,99223,741

SG&A incl. R&D (JPY Mn)

12,95014,87416,28617,59918,513

Operating profit (JPY Mn)

3,2173,8244,7095,3925,226

Ordinary profit (JPY Mn)

3,6584,2385,1185,5235,859

Pre-tax profit (JPY Mn)

3,6094,4095,2806,1546,590

Net profit attributable to owners (JPY Mn)

2,5463,1353,6554,3174,887

Comprehensive income (JPY Mn)

3,3663,5847,1572,4717,744

EPS basic (JPY, split-adjusted)

71.6188.05103.09121.52137.38

EPS diluted (JPY, split-adjusted)

71.1787.56102.62121.09136.97

DPS (JPY, split-adjusted)

19.528.5314960

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

57.559.059.959.459.4

SG&A ratio (%)

46.047.046.445.546.3

Operating margin (%)

11.412.113.413.913.1

Ordinary margin (%)

13.013.414.614.314.6

Net margin (%)

9.09.910.411.212.2

Income Statement and Margin Analysis (%) (FY2025–FY2026)

MetricFY2025FY2026

Depreciation & amortisation (JPY Mn)

1,0591,210

EBITDA (JPY Mn)

6,4516,436

EBITDA margin (%)

16.716.1

Liquidity & Coverage Ratios and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (JPY Mn)

40,70943,72750,09349,99457,706

Cash and deposits (JPY Mn)

9,0649,5789,71610,65310,121

Inventories (JPY Mn)

7,5548,39110,29011,58313,765

Short-term debt incl. current LTD (JPY Mn)

32590728100

Long-term debt (JPY Mn)

1,153281000

Total debt (JPY Mn)

1,4781,18828100

Net cash incl. short-term investments (JPY Mn)

7,5868,3909,43510,89210,264

Net assets (JPY Mn)

32,94035,51541,60942,73648,689

Intangible assets (JPY Mn)

427462524556619

Working capital (JPY Mn)

16,02516,27119,58622,30323,550

Book value per share (JPY)

920.77998.321,168.021,198.371,363.94

Equity ratio (%)

80.580.882.785.284.1

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (JPY Mn)

3,7363,1703,0893,4473,371

Investing cash flow (JPY Mn)

-1,288-1,290-1,295-914-2,070

Financing cash flow (JPY Mn)

-1,074-1,457-2,096-1,783-1,968

Cash & equivalents at year end (JPY Mn)

8,2088,8309,02410,0619,774

Cash Flow (FY2025–FY2026)

MetricFY2025FY2026

Purchase of PP&E (JPY Mn)

1,2293,433

Purchase of intangibles (JPY Mn)

88169

Free cash flow, OCF less PP&E (JPY Mn)

2,218-62

Dividends paid (JPY Mn)

1,3851,849

Share buybacks (JPY Mn)

00

Proceeds from sale of investment securities (JPY Mn)

8691,124

Total capex, accrual basis (JPY Mn)

—4,413

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE, company-reported (%)

8.19.29.510.310.7

ROA, net profit / avg. assets (%)

6.57.47.88.69.1

Current ratio (x)

4.613.744.505.274.74

Debt / equity (x)

0.0450.0330.0070.0000.000

Interest coverage, OP / interest expense (x)

268212214317327

Asset turnover (x)

0.720.750.750.770.74

Days sales outstanding

42.640.047.139.242.0

Days inventory outstanding

230.3236.0266.7269.2309.1

Days payables outstanding

28.328.435.728.629.1

Cash conversion cycle (days)

244.6247.6278.1279.8322.0

Consolidated payout ratio (%)

27.232.430.140.343.7

Financial Ratios (x) and Margin Analysis (%)

MetricFY2025FY2026

Net debt / EBITDA (x)

-1.69-1.59

ROIC, operating (%)

16.413.7

Effective tax rate (%)

29.625.7

Revenue by Region and Revenue by Region (%)

RegionFY2022FY2023FY2024

Japan (JPY Mn)

14,23315,02515,588

Europe (JPY Mn)

5,6596,3557,492

Asia & Oceania (JPY Mn)

4,9196,3897,758

North & Latin America (JPY Mn)

3,3253,9084,241

Overseas ratio (%)

49.452.655.6

Country / Region Details

Country / regionFY2025

Japan (JPY Mn)

16,011

China (JPY Mn)

5,689

United States (JPY Mn)

4,271

Germany (JPY Mn)

3,883

Other countries (JPY Mn)

8,843

Overseas ratio (%)

58.6

Region Overview

RegionFY2026

Japan (JPY Mn, derived)

17,112

North & Latin America (JPY Mn)

5,103

Europe (JPY Mn)

8,658

Asia (JPY Mn)

9,121

Revenue by Region

RegionQ1 FY2026Q1 FY2027

Japan (JPY Mn)

4,1424,620

North & Latin America (JPY Mn)

1,2241,407

Europe (JPY Mn)

1,9502,315

Asia (JPY Mn)

2,1892,445

Segment / Region Details

Segment / regionQ1 FY2027

Dental — Japan

4,291

Dental — Americas

1,377

Dental — Europe

2,315

Dental — Asia

2,262

Nail — Japan

303

Nail — Americas

30

Nail — Asia

182

Other — Japan

25

Group Entities

SubsidiaryNet sales FY2026 (JPY Mn)Ordinary profit (JPY Mn)Ordinary margin (%)

Shofu Dental Trading (Shanghai)

6,0431,28421.2

SHOFU Dental Corp. (US)

4,83266913.8

SHOFU Dental GmbH (Germany)

4,62177116.7

Per-Share Data and Valuation Multiples (x)

MetricFY2022FY2023FY2024FY2025FY2026

Fiscal year-end implied price (JPY, PER × EPS, split-adjusted)

7811,0131,4642,1141,676

Year-end P/E (x)

10.911.514.217.412.2

SHOFU 5-year TSR index (Mar 2021 = 100)

80.6107.1156.0225.7187.9

TOPIX incl. dividends index (Mar 2021 = 100)

102.0107.9152.5150.2202.2

Valuation Multiples

MultipleSHOFUBasis

P/E (trailing, TTM EPS ¥173.12 incl. securities gains)

13.0x

S&P TTM to Jun 2026

P/E (forward, company FY2027 EPS ¥133.66)

16.9x

Company guidance

P/B

1.57x

BVPS ¥1,433.31 at 30 Jun 2026

EV/Sales (TTM sales ¥41.28bn)

1.68x

EV ≈ ¥69.2bn

EV/EBITDA (TTM EBITDA ¥6.92bn)

10.0x—

Dividend yield (FY2027 forecast ¥67)

3.0%—

Nakanishi P/E (peer reference)

≈23x

finboard.jp, date of snapshot n.d.

Per-Share Data and Capital Markets Data (JPY)

MetricFY2022FY2023FY2024FY2025FY2026FY2027

DPS (JPY, split-adjusted; FY2027 = forecast)

19.528.531496067

Of which special/commemorative (JPY, split-adjusted)

1500512

Bucket Details

BucketAmount (JPY Mn)

Due within 1 year (current portion of long-term loans)

325

Due after 1 year (long-term loans)

993

Total borrowings

1,318

Undrawn committed credit lines

2,000

Analyst Conclusions

Management guidance

FY2027: net sales ¥42,958m (+7.4%), operating profit ¥6,003m (+14.9%, margin 14.0%), ordinary profit ¥5,890m (+0.5%), net profit ¥4,756m (−2.7%), DPS ¥67. Q1 FY2027 delivered 25.1% of full-year sales guidance and 32.4% of OP guidance; H1 OP guidance of ¥2,949m implies Q2 OP of only ~¥1.0bn, which appears conservative. The H1 net-profit guidance (¥2,552m) is already 84% achieved after Q1. Guidance was not revised at Q1 despite the beat, suggesting an upgrade at H1 is plausible. Fifth MTP target (FY2028): sales ¥50.1bn, OP ¥7.5bn, ROE 13.5%.

Consensus expectations

Consensus sits close to guidance for FY2027 (sales +7%, OP +14%), with a three-year revenue CAGR around 7%. At that pace, FY2028 sales would land around ¥46bn — short of the ¥50.1bn MTP target without acquisitions or significant FX help.

Bull case

  1. Operating re-acceleration is real: Q1 FY2027 dental sales +14.3% and dental margin 19.6% indicate FY2026 was a temporary air pocket; full-year OP could exceed ¥6.5bn versus ¥6.0bn guidance.

  2. Capital efficiency catalysts: cross-shareholdings (¥7.9bn) and net cash (¥11.2bn) together equal ~24% of market cap; continued disposals, rising payouts (FY2027 implied 50%) and an engaged shareholder (Neuberger Berman at 5.64%) could lift ROE toward 13.5% and support a P/B re-rating.

  3. M&A-driven scale-up: Vision10 explicitly requires non-organic growth; the debt-free balance sheet and Mitsui Chemicals backing give SHOFU firepower for accretive bolt-ons in digital dentistry, prevention and orthodontics.

Bear case

  1. China and FX: the most profitable overseas subsidiary (Shanghai) showed declining sales in Q1 FY2027; any yen strength would erode translated sales that are now ~59% of the total.

  2. Earnings quality and cash conversion: net-profit growth relies on securities gains (¥836m FY2026; ¥1,124m Q1 FY2027) and FY2026 FCF was negative; inventory at 309 days raises obsolescence and working-capital risk.

  3. Credibility of long-range targets: the ¥50bn vision has been deferred three times; Vision10's ¥250bn (6x scale-up) target may lead to over-priced acquisitions, while SG&A intensity limits organic margin expansion toward 20%.

Key catalysts and monitorables (next 12 months)

  • Q2 FY2027 results (expected early November 2026): potential guidance upgrade; China trajectory.

  • Integration of the implant business post-1 October 2026 and any digital-dentistry bundle launches.

  • Shiga Shofu plant completion (December 2026) and Kyoto plant progress; capex versus FCF.

  • Inventory trend (DIO) and operating cash flow.

  • Further cross-shareholding sales and special dividends; possible first buyback.

  • Any M&A announcement under Vision10.

  • New Fifth MTP progress update and FY2028 guidance (May 2027); possible Sixth MTP framing.

  • Board effectiveness after the June 2026 overhaul; investor engagement by Neuberger Berman.

  • Yen/USD/EUR/CNY exchange rates; Japan dental reimbursement revisions.

Analyst verdict

SHOFU is a high-quality, conservatively financed niche franchise caught between two identities: a century-old Japanese prosthetics and abrasives leader, and an aspiring global digital-dentistry platform. The financial record over FY2022–FY2026 is genuinely strong — revenue compounded at about 9%, net profit at about 18%, and ROE climbed from 8.1% to 10.7% — but FY2026 exposed the fragility beneath the headline records. Operating profit fell, net-profit growth leaned on cross-shareholding sales, inventories swelled to more than ten months of cost of sales, and capex pushed free cash flow below zero.

The first quarter of FY2027 materially improves the picture. Double-digit growth across every region by company location, a dental segment margin near 20%, and a raised dividend show that the operating engine has re-engaged. The new governance structure — a CEO/CFO model, a Sysmex CFO as independent director, and the end of the chairman role — signals more market-oriented management at a point where an engagement investor has built a 5.6% stake.

Valuation is undemanding rather than cheap: roughly 10x EV/EBITDA and 17x forward P/E on guidance that looks conservative, with about a quarter of the market capitalisation backed by net cash and listed securities. The principal swing factors are China, the yen, and whether management can convert excess capital into either higher returns or sensible acquisitions.

On balance, SHOFU merits a constructive but selective stance: the near-term set-up (likely guidance upgrade, rising payouts, continued unwinding of cross-holdings) is favourable, while the long-term thesis depends on disciplined execution of Vision10. Investors should demand evidence of inventory normalisation and positive free cash flow by FY2028, and should treat any large acquisition as the key test of capital discipline. Until then, SHOFU is best viewed as a steady compounder with optional upside from capital-policy reform rather than a transformational growth story.


Derived figures are arithmetic computations from disclosed data and should be checked against primary filings before use in investment decisions. This document is not investment advice.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleBorn (age)Board sinceBackgroundIndependent

Tetsuo Takami (髙見哲夫)

Representative Director, President & CEO

Jun 1960 (66)

2020

Joined 1983; Sales Dept head 2012; Tokyo Branch GM 2015; Managing EO Sales 2019; President since Jun 2022; CEO title added Jun 2026

No

Takahiro Umeda (梅田隆宏)

Representative Director, Executive VP & CFO (Finance, Nail business)

Feb 1960 (66)

2023

Bank of Kyoto branch manager; joined 2015 as Finance head

No

Hideji Sonoi (薗井秀次)

Director, Managing EO (Production)

Mar 1971 (55)

2024

Joined 1995; Executive Director of Merz Dental 2018

No

Ryuichi Yoshimoto (吉本龍一)

Director, Managing EO (R&D, Technology, Marketing)

Aug 1964 (62)

2026

Joined 1988; Technology head 2014; R&D head 2018

No

Hiroyoshi Miyake (三宅宏善)

Director, Managing EO (General Affairs, IT)

Apr 1967 (59)

2026

Joined 1990; Corporate Planning head 2020; outside director of Sun Medical

No

Daizo Nishimura (西村大三)

Outside Director; chairs Nomination & Remuneration Council

May 1959 (67)

2020

CPA/tax accountant; representative partner, Otemae Audit Corporation

Yes

Junko Yaguchi (矢口順子)

Outside Director

Apr 1963 (63)

2025

Salomon Brothers, Merrill Lynch, BNP Paribas; director of MINKABU THE INFONOID

Yes

Kensuke Iizuka (飯塚健介)

Outside Director

Mar 1970 (56)

2026

Sysmex Corporation Managing EO and CFO

Yes

Shingo Ono (小野真吾)

Outside Director

Feb 1976 (50)

2026

Mitsui Chemicals; GM Oral Care Business; former Kulzer GmbH supervisory board member

No (major shareholder executive)

Directors' Remuneration

CategoryTotal (JPY Mn)FixedPerformance bonusRestricted stockHeadcount

Inside directors

26916448565

Inside auditors

3838002

Outside officers

4242008

Board & Management Changes

DateChange

Jun 2025

Junko Yaguchi and Kaori Matsue (Mitsui Chemicals) join as outside directors; Mitsuo Kamimoto and Hiromi Hayashida retire

Apr 2026

Umeda's portfolio expanded to include IT

13 May 2026

Leadership transition announced: CEO/CFO titles introduced, "generational change" in governance

24 Jun 2026

Negoro (Chairman), Yamazaki (moves to EVP/CSO off-board), Suzuki and Matsue (outside) leave the board; Yoshimoto, Miyake, Iizuka and Ono join; EVP Kazuhiko Murakami (Sales & International) leaves the executive roster; auditor Shigeyuki Komatsu retires

Major Shareholders

RankShareholderShares (thousand)% of outstanding
1

Mitsui Chemicals, Inc.

7,16020.11
2

The Master Trust Bank of Japan (trust account)

2,4516.88
3

The Bank of Kyoto

1,4244.00
4

Nippon Life Insurance

1,2923.63
5

The Shiga Bank

1,2043.38
6

Northern Trust Co. (AVFC) re IEDP AIF Clients

8962.51
7

SHOFU Employee Shareholding Association

4961.39
8

Government of Norway

4751.33
9

BBH for Neuberger Berman Japan Equity Engagement Fund

4601.29
10

J. Morita Corporation

4571.28

Competitive Landscape

Key Competitors

CompetitorHQ / statusOverlap with SHOFU

Dentsply Sirona

US, NASDAQ

Restoratives, CAD/CAM, prosthetics, artificial teeth, abrasives

Envista (Kerr, Nobel Biocare)

US, NYSE

Restoratives, adhesives, polishing, implants

Ivoclar Vivadent

Liechtenstein, private

Composites, ceramics, CAD/CAM, artificial teeth

GC Corporation

Japan, private

Glass ionomers, composites, CAD/CAM, prosthetics — closest domestic rival

Kuraray Noritake Dental

Japan, subsidiary of Kuraray

Adhesives, zirconia (Katana), composites

Solventum (formerly 3M Health Care)

US, NYSE

Restoratives, adhesives, CAD/CAM, orthodontics

Kulzer (Mitsui Chemicals)

Germany, subsidiary of Mitsui Chemicals

Composites, denture teeth, lab materials — also an alliance-adjacent party

Tokuyama Dental

Japan, subsidiary of Tokuyama Corp.

Composites, adhesives

VOCO GmbH

Germany, private

Composites, cements

Coltene Holding

Switzerland, SIX

Restoratives, endodontics, rotary instruments

Nakanishi Inc.

Japan, TSE Prime 7716

Rotary instruments and equipment (also a partner and cross-shareholding)

Straumann Group

Switzerland, SIX

Implants, CAD/CAM, clear aligners (relevant to SHOFU's implant/digital ambitions)

Peer Comparison FY2024

CompanyRevenueRevenue growthOperating marginR&D intensitySource / period

SHOFU

¥40.0bn

+3.3%13.1%5.4%

Yuho, FY3/2026

Nakanishi

¥81.2bn

+5.4%17.4%—

Company results, FY12/2025 (net loss of ¥2.4bn due to ¥13.7bn impairment)

Dentsply Sirona

≈US$3.8bn

Declining (n.d. precise)

——

FY2024 company report

Envista

≈US$2.5bn

———

FY2024 company report

Straumann

≈CHF 2.5bn

———

FY2024 company report

Recent Developments

--

Company Snapshot

$267.2M

Revenue

1,462

Employees

1922

Founded

Kyoto, Japan

Headquarters

SWOT Analysis

Strengths

  • Record earnings: FY2026 net sales ¥39,994m and net profit ¥4,887m were all-time highs (Yuho FY2026).
  • Balance-sheet strength: zero financial debt at 31 March 2026; net cash ¥10.3bn; equity ratio 84.1%.
  • High gross margin: 59.4% in FY2026, up from 57.5% in FY2022.
  • Diversified geography: overseas share rose from 49.4% (FY2022) to 58.6% (FY2025); three overseas subsidiaries each exceed 10% of group sales.
  • Innovation cadence: more than ten new or renewed dental products launched in FY2026 across restoratives, prevention, ortho, ceramics and software.
  • Strategic anchor shareholder: Mitsui Chemicals at 20.11% under a 2020 alliance covering R&D, sales and production.
  • Profitable China channel: Shofu Dental Trading (Shanghai) generated ¥1,284m ordinary profit on ¥6,043m sales.

Weaknesses

  • Operating profit declined 3.1% in FY2026 despite record sales, as SG&A rose to ¥18,513m.
  • Inventory build: inventories up 82% FY2022–FY2026 versus +42% sales; DIO at 309 days.
  • Negative FCF of −¥62m in FY2026 (OCF ¥3,371m vs PP&E capex ¥3,433m).
  • Loss-making nail segment: operating loss ¥113m in FY2026, widening; ¥105m impairment.
  • ROE of 10.7% well short of the 13.5% FY2028 target and the reported ~8–10% cost-of-capital comfort zone for Prime-listed firms.
  • Low female management representation: 3.9% of parent-company managers; gender pay gap at 53.7% (all workers).
  • Repeated deferral of the ¥50bn target (2022 → 2027 → FY2028).

Opportunities

  • Q1 FY2027 rebound: sales +13.5% and OP +30.0%, with Europe +18.7% and Japan +11.5%.
  • Vision10 M&A optionality: net cash ¥11.2bn plus undrawn ¥2bn credit line supports bolt-on acquisitions in digital, preventive and ortho.
  • Implant integration: SHOFU BIOFIX absorbed October 2026 to offer digital-dentistry system solutions.
  • New markets: Middle East & Africa subsidiary (2026), India (142 employees), Brazil and Mexico.
  • Capacity: Kyoto plant phase 1 complete, Shiga plant due December 2026 — enabling ¥31.4bn overseas sales target.
  • Capital release: cross-shareholdings of ¥7.9bn (16.3% of net assets) to be cut to ~10%, funding capex and special dividends.
  • Japanese CAD/CAM reimbursement: domestic growth driven by PEEK and hybrid-resin blocks.

Threats

  • China slowdown: China sales declined YoY in Q1 FY2027.
  • FX: yen strength would reduce translated overseas sales (management flags this explicitly).
  • Geopolitics/trade: Middle East conflict impact on Europe; US tariff uncertainty (Yuho FY2026).
  • Competition: global CAD/CAM and composites competition intensifying; US nail market flooded by cheap gels.
  • Regulatory: stricter EU rules on nail raw materials; potential plastic regulation affecting products in Europe (TCFD scenario analysis).
  • Healthcare cost containment: price-cut pressure from insurers and governments (Yuho risk factor 5).
  • Execution risk on Vision10: requires ~6x scale-up from FY2026, implying large M&A with integration risk.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
10 Apr 2025Board resolves not to renew takeover-defence plan (lapses at June 2025 AGM)Governance improvement; responsive to investors
9 May 2025Updated capital-efficiency plan: ROE target 13.5% by FY2028; liquidity and return measuresSets the bar for re-rating
May 2025FY2025 results: record sales ¥38,698m (+10.3%), OP ¥5,392m (+14.5%), NP ¥4,317m (+18.1%)Peak-growth year
25 Jun 2025AGM: new outside directors Yaguchi and Matsue; new compensation caps including ¥70m restricted stockBoard refresh
Jul 2025Merssage Pro prophylaxis paste range renewedPreventive portfolio
Aug 2025SHOFU Etchant, Vintage Art Universal Gum launched; BEAUTIFIL II LS launched in Europe; Go2 dental updateProduct cadence
Early Aug 2025Q1 FY2026: sales +0.5%, OP −3.6%, NP −23.7%; full-year guidance keptFirst sign of slowdown
Sep 2025PTM kit renewal; Beauty Ortho Attachment; Shaburio oral trainerPrevention and ortho
28 Oct 2025H1 forecast revised: sales cut to ¥19,095m; NP raised to ¥2,597m on early cross-shareholding salesTop-line weakness masked by gains
6 Nov 2025H1 results: sales +1.1%, OP −7.5%, NP +9.9%; interim DPS ¥21Confirms soft operating trend
Nov 2025PRESTO nail line additions; Plump Top GelNail turnaround effort
Dec 2025EvenForce NT spring; SHOFU Tube; Go2 dental updateOrtho expansion
19 Dec 2025Vision10 announced: ¥250bn sales and 20% margin by 2040Bold long-term ambition implying M&A
1 Jan 2026Smart Dentistry Solutions merged into SHOFU Dental Corp.US simplification
4 Feb 2026Q3 results: 9M sales +0.9%, OP −11.4%; FY ordinary-profit forecast ¥5,363m kept (below consensus)Trough quarter (Q3 OP ¥993m)
Mar 2026Kyoto new plant phase 1 (SMILE FACTORY TAKUMI) completedCapacity for overseas demand
FY2026¥105m impairment on Nail Labo assetsNail business under pressure
1 Apr 2026Neuberger Berman files large-shareholding report (5.64%)Engagement investor on register
13 May 2026FY2026 results: record sales ¥39,994m, ordinary ¥5,859m (beat consensus ¥5,524m), NP ¥4,887m; DPS ¥60 incl. ¥5 special; FY2027 guidance OP ¥6,003mReturn to growth guided
13 May 2026Management transition announced (CEO/CFO titles; generational board change)Succession signal
20 May 2026Year-end dividend ¥39 resolved by boardPayout 43.7%
23 Jun 2026Yuho FY2026 filedAnnual disclosure
24 Jun 2026AGM: Iizuka (Sysmex CFO) and Ono (Mitsui Chemicals) join; Chairman Negoro steps down; auditor board cut to threeGovernance reset
9 Jul 2026Board resolves to absorb SHOFU BIOFIX effective 1 Oct 2026Implants into core
Q1 FY2027New long-term borrowings of ¥1,318mFirst debt since FY2024; plant funding
5 Aug 2026Q1 FY2027: sales +13.5%, OP +30.0%, NP +151.3% (incl. ¥1,124m securities gain); China sales declinedStrong rebound
5 Aug 2026Dividend forecast raised to ¥67 (interim special raised from ¥6 to ¥12)Shareholder return escalates
29 Sep 2026Ex-dividend date for ¥39 interim—
1 Oct 2026SHOFU BIOFIX merger effective (scheduled)Digital/implant integration
Dec 2026 (planned)Shiga Shofu new plant completionCapacity
Early Nov 2026 (expected)Q2 FY2027 resultsNext catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

9 charts
Revenue by Segment (FY2025–FY2026): Dental net sales rose from JPY 36,356 Mn in FY2025 to JPY 37,669 Mn in FY2026.
Shofu Inc. — Revenue by Segment (FY2025–FY2026)
Series (JPY Mn)FY2025FY2026
Dental net sales36,35637,669
Nail net sales2,2432,225
Other net sales9899
Dental operating profit5,4385,334
Nail operating profit-67-113
Other operating profit140

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.